“The nicotine molecule is too small to affect an immune response. By soaking it up, our carrier protein creates a molecule that is too big to break the blood-brain barrier.”
“We believe this is the first Fast Track Designation for a smoking cessation product candidate, which is unprecedented, and provides further validation for our unique approach to addressing nicotine addiction.”